PSNL News and Press, Personalis Inc. From 07/16/20

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted sto...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment of Leslie Grab as VP of Intellectual Property and John Lyle as VP of Assay Research and Development. Dr. Grab joins Personalis from Verily Life Sciences (a Google spin-out), where sh...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced its completion of the 75,000 th whole human genome sequenced under its contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). All genomes were...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held online, June 22-24,...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020. Personalis will present “Enabling...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020. Personalis will present “Enabling multidimensional tumor immunogenomics...

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on June 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 67,900 shares of its common stock and restricted sto...

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the partnership with Berry Genomics, headquartered in the People’s Republic of China. Personalis will be expanding business operations in the People’s Republic of China in 2020, and pla...

Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with Sarepta Therapeutics (Nasdaq: SRPT), a leader in precision genetic medicine for rare disease. As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precis...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020. One abstr...